Pharmaceutical Composition of an Aldose Reductase inhibitor and an inhibitor of glycogen phosphorylase, and Equipment containing those inhibitors

摘要

1. This material is aimed at pharmaceutical components containing reduced aldehyde inhibitors and glucose phosphate inhibitors, as well as such compounds used to treat insulin-resistant diseases in mammals (such as humans), including diabetes. Men or women) or use this synthesis to reduce tissue damage (for example,Basic prevention of tissue injury or induced tissue dislocation (tissue tear) The combination includes a therapeutically effective slug reduction inhibitor and a glucose phosphate inhibitor. Reducing aldehyde inhibitors may be, but are not limited to, 1-o-phenylpropionic acid, 3,4-dihydro-4-oxo-3 - [(5-trifluoro-octane sulfonic acid) - 2-benzo-parathion] methyl]. Polyphosphate inhibitors include compounds containing (I) and (H) a pharmaceutically acceptable formulation in which the filament (- -) is an optional link; a es-c (H = 1-(C1-4 tar) = 0-c (halogenation) = when the drag line (- -) is a link, or when the drag line (- -) is not a link, a is toluene o-ch (C1-4 tar) = each R1, R10 or r11es, independent, h, halogenated, 4 -,Page: 1C11-1-11 11-11-11-11 11-1-1-1-11-1-1-1-1-1-4 or fur-2-o-3-1-tar C1-4, In those lovely places around R4Di-o tri-replace independent carbon with H, halo, C1-4 hydrocarbon, alcoxi C1-4, trifluoroide, hydroxy, amino or cyanogen; or R4 is pirid-2 -,-3-O 4-1-C1-4-1-1-4- or-5-yl-C1-4alkyl, imidazol-1-,-2...-4- o -5-il-alquilo C1-4 pirrol-2- o -3-il-alquilo C1-4 oxazol-2--4- or-5-yl-C1-4alkyl, pyrazole-3-,-4-o-5-1-c1-4, isoxazol-3-4-o-5-1-c1-4, isodiazole-3-4- or -5-yl-C1-4-alkyl, pyridazin-3- or -4-yl-C1-4-alkyl, pyrimidin-2-,-4...-O-6-l-